Even people living with HIV who have undetectable viral loads experience elevated inflammation levels, explained Michelle Cespedes, M.D., M.S, of Mount Sinai Health System.

Only a small group of patients have started the process to receive the new gene therapies for sickle cell disease, says Kevin Niehoff, Pharm.D., of IPD Analytics.

Drs Martin Rosenzweig and Samuel Nordberg share perspectives for integrated policymaking in behavioral health, as well as payer and provider collaboration for TRD.

Carrie Jardine leads a discussion on varying prior authorization policies for alternative therapies for TRD along with implications to patients.

Key opinion leaders discuss navigation through challenges with appropriate coding for TRD treatment.

Carrie Jardine and Martin Rosenzweig, MD, share considerations for benefit design in behavioral health.

Dr Patricia Ares-Romero and Dr Martin Rosenzweig discuss treatment strategies for TRD, including alternative therapies and explain current barriers within the healthcare system that inhibit access.

A medical expert in infertility discusses how best practices in communicating benefits for fertility treatments and assisted reproductive technology (ART) programs involve clear, concise and accessible information delivery and tailoring messages to diverse patient populations to ensure comprehensive understanding of coverage options and treatment processes.

Jeffrey Dunn, Pharm.D., MBA, discusses how social determinants of health and population health factors are integrated into decision-making processes for fertility treatments and assisted reproductive technology (ART) programs to ensure equitable access and improve overall outcomes across diverse patient populations.